Thread by @ctfn_news

CTFN's #ICYMI weekend edition: #Merger and deal activity are expected to be robust in 2021, and regulator scrutiny is expected to be rigorous.

(thread) #antitrust #investming #stocks

In the meantime, key changes will occur under the new #Biden administration at the U.S. Federal Trade Commission that is anticipated to weigh heavily on big pharma deals, @dalter28 wrote

#FTC #antitrust #MnA

Further for one big pharma deal, Surani Fernando wrote that while @AstraZeneca's $39 billion bid for @AlexionPharma has drawn a number of critics, a strategic build-out of immunology may prove an important rationale for the deal

#mergers #healthcare $ALXN $AZN

On @Google's acquisition of @Fitbit: the @acccgovau rejected #Google's offer of behavioral remedies this week, though a former ACCC official walked CTFN through how the parties might handle the review

#HeyGoogle #ACCC

The Russian regulatory process for Nova Resources' proposed buyout of Kaz Minerals is unlikely to exceed the standard timeline, CTFN's @CamerinoValeria reported

#shareholders #mergers #mining

Apollo upped the ante and boosted its offer for @GRTCanadian from C$39 to C$45, thus winning shareholder support this week. Negotiations with large shareholders came down to the wire, @dalter28 reported

#mergers #privateequity #casinogames

.@dalter28 also reported on the tussle over the Bristol Myers Squibb CVR trustee. The CVRs are up against a key milestone of December 31 for liso-cel approval.

@bmsnews #BMS #FDA

Make sure to check out CTFN's Daily page for updates on event-driven and #MnA related content, key regulatory information, and sourced tidbits from our editorial, reporting, and analyst staff, curated by our Director of Research @Tyler_Tulenko

#stocks #StocksToWatch #mergers

To discuss anything related to CTFN, our coverage, or how to put our resources to work for you, write to [e-mail].

#finance #MnA #antitrust